产品
编 号：F755544
分子式：C13H25ClN2O3
分子量：292.8
分子式：C13H25ClN2O3
分子量：292.8
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 2759182-59-5
产品详情
生物活性：
Neboglamine (CR-2249, XY-2401) hydrochloride is an orally active NMDA receptor glycine site positive modulator that can be used in schizophrenia research.
体内研究：
Neboglamine hydrochloride (s.c. or p.o., 0.3-30 mg/kg) can regulate neuronal activity in brain regions and inhibit PCP-induced hypermobility in rats.Animal Model:Male Wistar rats
Dosage:20 mg/kg
Administration:Subcutaneous injection
Result:Increased neuronal activity in brain regions, prefrontal cortex (PFCX) from 38.5 to 121.3, nucleus accumbens (NAc) from 14.5 to 69.1 and lateral septal nucleus (LSN) from 16.2 to 73.1 but no effect on dorsolateral striatum (DL-STR) compared to the control group.Significantly inhibited phencyclidine-induced hypermobility.
Animal Model:Male Wistar rats
Dosage:0.3 mg/kg, 3 mg/kg, 30 mg/kg
Administration:Oral administration
Result:Reduced frequency of PCP-induced hypermobility and stereotyped behaviour in a dose-dependent manner and the dose inhibited stereotyped behaviour (0.3 mg/kg) was lower than the dose inhibited motor activity (3 mg/kg).
Neboglamine (CR-2249, XY-2401) hydrochloride is an orally active NMDA receptor glycine site positive modulator that can be used in schizophrenia research.
体内研究：
Neboglamine hydrochloride (s.c. or p.o., 0.3-30 mg/kg) can regulate neuronal activity in brain regions and inhibit PCP-induced hypermobility in rats.Animal Model:Male Wistar rats
Dosage:20 mg/kg
Administration:Subcutaneous injection
Result:Increased neuronal activity in brain regions, prefrontal cortex (PFCX) from 38.5 to 121.3, nucleus accumbens (NAc) from 14.5 to 69.1 and lateral septal nucleus (LSN) from 16.2 to 73.1 but no effect on dorsolateral striatum (DL-STR) compared to the control group.Significantly inhibited phencyclidine-induced hypermobility.
Animal Model:Male Wistar rats
Dosage:0.3 mg/kg, 3 mg/kg, 30 mg/kg
Administration:Oral administration
Result:Reduced frequency of PCP-induced hypermobility and stereotyped behaviour in a dose-dependent manner and the dose inhibited stereotyped behaviour (0.3 mg/kg) was lower than the dose inhibited motor activity (3 mg/kg).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备